Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Esophageal post-inflammatory polyposis in extensive and severe Crohn's disease treated with anti-tumor necrosis factor alpha.

Soriani P, Tontini GE, Neumann H, Ishaq S, Annunziata ML, Pastorelli L, Vecchi M.

Endoscopy. 2016;48 Suppl 1:E261-2. doi: 10.1055/s-0042-110487. Epub 2016 Aug 4. No abstract available.

PMID:
27489996
2.

Treatment of severe esophageal Crohn's disease with thalidomide.

Ginsburg PM, Hanan I, Ehrenpreis ED.

Am J Gastroenterol. 2001 Apr;96(4):1305-6. No abstract available.

PMID:
11316198
3.

[Esophageal lesions in Crohn's disease and ulcerative colitis].

Valitova ER.

Eksp Klin Gastroenterol. 2011;(3):136-41. Review. Russian.

PMID:
21695963
4.

Crohn's esophagitis: a unique cause of esophageal polyposis.

Walker RS, Breuer RI, Victor T, Gore RM.

Gastrointest Endosc. 1996 May;43(5):511-5. No abstract available.

PMID:
8726770
5.

[Esophageal Crohn's disease].

Gil-Simón P, Barrio J, Saracíbar E, Pérez-Miranda M, Julián L, Antonio Gil Ruiz J, Caro-Patón A.

Gastroenterol Hepatol. 2008 Feb;31(2):108-9. Spanish. No abstract available.

PMID:
18279653
6.

Crohn's disease with isolated esophagus and gastric involvement.

Akbulut S, Yavuz B, Köseoğlu T, Gököz A, Saritaş U.

Turk J Gastroenterol. 2004 Sep;15(3):196-200.

7.

Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.

af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M.

Scand J Gastroenterol. 2012 May;47(5):528-37. doi: 10.3109/00365521.2012.660542. Epub 2012 Feb 23.

PMID:
22356594
8.

Successful use of thalidomide for refractory esophageal Crohn's disease.

Barkin JA, Schonfeld WB, Deshpande AR.

Am J Gastroenterol. 2013 May;108(5):855-7. doi: 10.1038/ajg.2013.49. No abstract available.

PMID:
23644969
9.

[Efficacy of tumor necrosis factor-alpha inhibitors in fistulising perianal Crohn's disease].

Bor R, Farkas K, Bálint A, Szűcs M, Abrahám S, Baradnay G, Wittmann T, Szepes Z, Nagy F, Molnár T.

Orv Hetil. 2013 Dec 8;154(49):1943-8. doi: 10.1556/OH.2013.29770. Hungarian.

PMID:
24292112
10.

Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.

Fanning SB, Chapman G, Yau Y, Leong RW.

J Gastroenterol Hepatol. 2010 Jan;25(1):215. doi: 10.1111/j.1440-1746.2009.06098.x. No abstract available.

PMID:
20136975
11.

Esophageal polyps in pediatric patients undergoing routine diagnostic upper gastrointestinal endoscopy: a multicenter study.

Septer S, Cuffari C, Attard TM.

Dis Esophagus. 2014 Jan;27(1):24-9. doi: 10.1111/dote.12066. Epub 2013 Apr 2.

PMID:
23551692
12.

Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.

Włodarczyk M, Sobolewska A, Wójcik B, Loga K, Fichna J, Wiśniewska-Jarosińska M.

World J Gastroenterol. 2014 Jun 14;20(22):7019-26. doi: 10.3748/wjg.v20.i22.7019.

13.

[Fifteen years of use of anti-TNF antibodies in moderate to severe Crohn's disease: how to make the best of this experience].

Louis E, Reenaers C, Meuwis MA, Van Kemseke C, Latour P, Chapelier N, Wertz S, Coïmbra C, Meunier P, Belaiche J.

Rev Med Liege. 2012;67 Spec No:8-13. French.

14.

Oral ulcerations are associated with the loss of response to infliximab in Crohn's disease.

Sánchez AR, Rogers RS 3rd, Sheridan PJ.

J Oral Pathol Med. 2005 Jan;34(1):53-5.

PMID:
15610407
15.

Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.

Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A.

Dig Liver Dis. 2014 Nov;46(11):974-9. doi: 10.1016/j.dld.2014.07.013. Epub 2014 Aug 2.

PMID:
25096964
16.

[Hodgkin's lymphoma in a patient with Crohn's disease treated with azathioprine and antibodies anti tumor necrosis factor α].

Sagüés M, Navarro JT, Ribera JM, Millá F.

Med Clin (Barc). 2012 Apr 7;138(8):366-7. doi: 10.1016/j.medcli.2011.05.005. Epub 2011 Jul 12. Spanish. No abstract available.

PMID:
21752407
17.

The natural history of esophageal Crohn's disease: three patterns of evolution.

D'Haens G, Rutgeerts P, Geboes K, Vantrappen G.

Gastrointest Endosc. 1994 May-Jun;40(3):296-300.

PMID:
8056231
18.

Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.

af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M.

Scand J Gastroenterol. 2013 May;48(5):543-51. doi: 10.3109/00365521.2013.772230. Epub 2013 Mar 12.

PMID:
23477356
19.

Dysphagia and esophageal ulceration in Crohn's disease.

Gelfand MD, Krone CL.

Gastroenterology. 1968 Oct;55(4):510-4. No abstract available.

PMID:
5698629
20.

[Esophageal involvement in Crohn's disease].

Kersjes W, Harder T, Wolf J.

Rofo. 1987 Aug;147(2):221-2. German. No abstract available.

PMID:
2819986

Supplemental Content

Support Center